Datamonitor October edition of The Licensing Review contains news, analysis and opinions on the healthcare licensing industry.

Scope

• Strategic insight into the future shape of healthcare companies and markets

• The most significant healthcare licensing news compiled into one monthly update

• Expert analysis into the implications of the month's important healthcare licensing events

• Insight into the future shape of the market for players at all levels

• All the month's healthcare licensing stories in headline and summary form

Report Highlights

Out of the dozens of topics covered in this month's review, the most important include:

* Watson Pharmaceuticals entered into a licensing and supply arrangement with Elan granting Watson the exclusive US rights to the 30mg and 60mg dosage strengths of Elan's extended-release nifedipine tablets, the generic version of Bayer's Adalat CC, indicated for the treatment of hypertension.

* Merck's CEO calls for more private sector action to tackle AIDS epidemic. He suggested that pharmaceutical companies should join forces with United Nations Agencies, big business and governments to tackle the growing AIDS epidemic raging in southern Africa.

Reasons to Purchase

• Not only keeps you updated about industry events - it also gives you opinion and insight

• Draws upon Datamonitor analysts' extensive experience to bring you our perspective on the impact of the latest events

• Provides you with your own news archive to track company and industry progress, giving you an extensive reference to relevant events and issues

R&D UPDATE: HIV

The most significant news in HIV R&D, compiled into one monthly update.

R&D UPDATE: HEPATITIS

The most significant news in hepatitis R&D, compiled into one monthly update.

R&D UPDATE: BACTERIAL INFECTIONS

The most significant news in bacterial infections R&D, compiled into one monthly update.

R&D UPDATE: FUNGAL INFECTIONS

The most significant news in fungal infections R&D, compiled into one monthly update.

R&D UPDATE: OTHER INFECTIOUS

The most significant news in other infectious R&D, compiled into one monthly update including:

• Malaria

• Smallpox

LATEST COMMENT

Expert analysis of the implications of the month's important industry events

• Cipla: lobbying for more generics in South Africa

• Alternative therapies: hurting HIV regimes

• HIV treatment: non-compliance brings pitfalls without benefits

• Lilly: no European rebirth for Xigris

• Bayer: seeking Gamunex approval

FEATURE ANALYSIS

Analyst-written feature articles, featuring the latest insights into the industry

• HIV: the crisis continues

NEWS HEADLINES - HIV

All the month's HIV news stories in headline and summary form

NEWS HEADLINES - HEPATITIS

All the month's hepatitis news stories in headline and summary form

NEWS HEADLINES - BACTERIAL INFECTIONS

All the month's bacterial infections news stories in headline and summary form

NEWS HEADLINES - FUNGAL INFECTIONS

All the month's fungal infections news stories in headline and summary form

NEWS HEADLINES - OTHER INFECTIOUS

All the month's other infectious news stories in headline and summary form

To order - click here!